Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/31/2024 | $36.00 | Buy | Chardan Capital Markets |
4 - MeiraGTx Holdings plc (0001735438) (Issuer)
Received 3 Rare Pediatric Disease Designations (RPDD) from FDA for each of 3 potential therapies for 3 different rare inherited retinopathies including AAV-AIPL1 Agreed on pathway with MHRA for Marketing Authorization Application (MAA) under exceptional circumstances for AAV-AIPL1 for the treatment of Leber congenital amaurosis (LCA4) retinal dystrophy without further clinical studies Announced positive data from randomized, sham-controlled clinical bridging study of AAV-GAD for the treatment of Parkinson's disease LONDON and NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage genetic medicines company, today announced
LONDON and NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the Company will exhibit five posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress, which is being held from October 22-25, 2024, in Rome, Italy. The posters are available on the Posters and Publications page of the Company's website. The details of the poster presentations are as follows: Poster Number: P0015Abstract Title: Evolution of a high-producing, modular upstream platform for AAV manufacturingPoster Session III: Tuesday 22 October from 19:30 to 21:00 CESTAbstract:The
The primary study objective of safety and tolerability was met Significant and clinically meaningful improvements from baseline demonstrated for key efficacy endpoints at 26 weeks Significant improvement of 18 points in Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 in the high dose group at 26 weeks Significant improvement in the Parkinson's Disease Questionnaire (PDQ-39) score, a key quality of life measure, for both the high and low dose groups at 26 weeks LONDON and NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced top-line data from its clinical bridging stu
4 - MeiraGTx Holdings plc (0001735438) (Issuer)
3 - MeiraGTx Holdings plc (0001735438) (Issuer)
4 - MeiraGTx Holdings plc (0001735438) (Issuer)
10-Q - MeiraGTx Holdings plc (0001735438) (Filer)
8-K - MeiraGTx Holdings plc (0001735438) (Filer)
8-K - MeiraGTx Holdings plc (0001735438) (Filer)
Chardan Capital Markets resumed coverage of MeiraGTx with a rating of Buy and set a new price target of $36.00
SC 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)
SC 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)
SC 13D/A - MeiraGTx Holdings plc (0001735438) (Subject)
Clinically meaningful improvements in xerostomia symptoms measured by two different xerostomia PROs demonstrated across both unilaterally and bilaterally treated cohorts at 12 monthsIncreases in whole saliva flow rates observed post-treatment, providing objective evidence of biological activity, reaching the normal range in bilaterally treated participants by 2 months and persisting through the Month 12 assessmentAcross assessments, greater improvements observed in bilaterally treated participants compared to those treated unilaterally Early long-term follow-up data suggest durability of improvement to at least 3 years post-treatmentAAV2-hAQP1 appears safe and well tolerated at each dose te
LONDON and NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to present an update on the Company's AAV-hAQP1 clinical program for the treatment of grade 2/3 radiation-induced xerostomia (RIX) on Tuesday, June 27, 2023, at 8:00 a.m. ET. The presentation will include: 1) Data from the completed Phase 1 AQUAx clinical study for the 24 patients treated with AAV-hAQP1 in the unilateral and bilateral cohorts: Safety and tolerability12-month data for PRO assessments of xerostomia symptoms in the unilateral cohorts (n=12)12-month data for
Clinically meaningful improvements in xerostomia symptoms and disease burden reported in patient reported outcome (PRO) measures in both unilateral and bilateral cohortsIncreases in whole saliva flow rates were seen in both unilateral and bilateral cohorts Overall degree of improvement was greater in bilateral compared to unilateral cohorts AAV2-hAQP1 appears safe and well tolerated at each dose tested Webcast and conference call to be held today, December 13, 2022, at 8:00 a.m. ET LONDON and NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced positive clinical data from the ongoin
Company cofounder and CTO to lead button battery safety tech company toward commercialization The Directors of Landsdowne Labs, LLC, are pleased to announce the appointment of Bryan Laulicht to Chief Executive Officer. Laulicht, a company cofounder, has served as Lansdowne's Chief Technology Officer since the company's formation in 2017. He has also co-founded and served in leadership positions at two other companies focused on applying biophysics and bioengineering approaches to fulfilling unmet medical and safety needs. Both of those companies have been acquired for a combined total greater than $500M. Lansdowne's technology, applied to small, coin-like "button" batteries, is design
LONDON and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Dr. Debra Yu to its Board of Directors. Dr. Yu currently serves as President and Chief Strategy Officer of LianBio, and previously served as LianBio's President and Chief Business Officer. Dr. Yu has more than 30 years of healthcare industry experience in business development, alliance management, investment banking and capital markets. She has held senior positions at Pfizer in its Worldwide Business Development organization and Labrador Advisors, LLC, where she advised numerous partnerships and licen
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Dutch Bros Inc. (NYSE:BROS). On May 7, Dutch Bros posted better-than-expected first-quarter financial results and raised its full-year revenue guidance. “The outlook is fabulous. There is a lawsuit in July that, involving formula,” Cramer said when asked about Abbott Laboratories (NYSE:ABT). “We're waiting until at least it gets to par or 100 to be able to buy more. But we believe in the company.” On April 17, Abbott Laboratories reported better-than-expected earnings for its first quarter. The company posted first-quarter sales of $9.96 billion, up 10.8% on an organic basis for the underlying base business, beatin
MeiraGTx Hldgs (NASDAQ:MGTX) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.50) by 36 percent. This is a 48.39 percent increase over losses of $(0.62) per share from the same period last year. The company reported $697.00 thousand in sales this quarter. This is a 79.09 percent decrease over sales of $3.33 million the same period last year.
RBC Capital analyst Luca Issi reiterates MeiraGTx Hldgs (NASDAQ:MGTX) with a Outperform and maintains $11 price target.